Delic Corp (DELC.C) announced that their wholly-owned subsidiary, DELIC Labs, has entered into a partnership agreement with Agilent.
Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, and they specialize in pharmaceuticals, research, and diagnostics, among other things.
The agreement is a “you scratch my back, I’ll scratch yours” type of deal. Agilent will refer its clients interested in cannabis and hemp analytics and new product development to DELIC Labs and DELIC Labs will recommend Agilent’s analytical equipment to its clients looking to purchase new systems.
“Partnering with Agilent, the dominant global analytics experts, is a powerful step for DELIC Labs and brings our cannabis and hemp experience to their broad range of clients, including large pharmaceutical companies,” stated DELIC Labs founder and CEO Dr. Markus Roggen. “Our combined expertise will help solve many issues for those exploring the cannabis industry and developing new and unique products to serve an increasingly growing consumer and patient base.”
The services Agilent will be referring clients for is DELIC Labs’ licensed cannabis analytical laboratory, which offers in-depth analysis and precise characterization of the chemical makeup of your plant material and products. As DELIC Labs notes, their testing goes beyond the basic requirements outlined by Health Canada, as they assist with eliminating impurities, adjusting concentrations, and optimizing extraction and manufacturing processes.
DELIC Labs also runs the Cannabis Compound Database, which includes information about more than 750 compounds found in the cannabis plant and allows users to find important information about
“We continually strive to meet the needs of our customers and there has been a significant interest in cannabis and hemp analytics as well as new product development,” commented Greg Kozadjian, Emerging Markets, Business Development, Agilent Technologies. “Partnering with the team at DELIC Labs is a natural fit as they are at the forefront of legal cannabis analytics and research. We are excited to leverage their domain expertise.”
Just yesterday, Delic completed their rebranding of what was previously known as Complex Biotech Discovery Ventures (CBDV) to DELIC Labs, after Delic acquired CBDV for $7 million in DELC share capital. Delic bought CBDV to function as the “engine” of their business. With this deal, Agilent is going to be sending fuel to that engine.
“Agilent is well-regarded as the premier scientific destination for analytical science and we are honored to collaborate with them through our team at DELIC Labs,” stated Matt Stang, Delic CEO and co-founder. “Delic is committed to bringing innovative natural wellness remedies to the general public and this partnership will open up enterprise opportunities for pioneering companies.”
Following the news, there has been no change in Delic’s share price.
Full Disclosure: Delic Holdings is an Equity Guru marketing client.